FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
This action demonstrates the agency’s commitment to moving with urgency, reducing unnecessary delays and advancing innovative treatments that can make a meaningful difference in the lives of American patients and their families.
The approval provides a new treatment option for patients with metastatic pancreatic adenocarcinoma, a form of pancreatic cancer that remains highly lethal and historically difficult to treat.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.